Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury

Contact patients currently taking Esmya for uterine fibroids as soon as possible and advise them to stop their treatment.

Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections

Caution should be used in patients with known risk factors for venous thromboembolism in addition to the underlying disease.

Baricitinib (Olumiant▼): risk of venous thromboembolism

Discontinue baricitinib treatment permanently if clinical features of deep vein thrombosis or pulmonary embolism occur.

SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness

SGLT2 inhibitor treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses and ketone levels measured, preferably in blood rather than urine.

Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

Benzodiazepines and opioids can both cause respiratory depression, which can be fatal if not recognised in time.

Letters and drug alerts sent to healthcare professionals in February 2020

Letters were sent on Typhim Vi vaccines, Mepact (mifamurtide), and Xeljanz (tofacitinib) and an alert issued to recall Emerade 150 microgram adrenaline pens.

Medical Device Alerts issued in February 2020

Alerts were issued about CME T34 and T34L (T60) ambulatory syringe pumps, Cardinal Health tympanic thermometers, t:slim X2 insulin pump, and Mavidon skin preparation electrode gels.

Posted on the UK MHRA website on 18 March 2020